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Clinical Note

Potency of Current Levothyroxine Preparations Evaluated by
High-Performance Liquid Chromatography
Sheldon S. Stoffer, MD,* and Walter E. Szpunar, PhD*

Ten different levothyroxine products manufactured by six companies were analyzed by highperformance liquid chromatography. Although nine products met the United States Pharmacopeia
requirements, one product was found to have only 47% of expected potency. Until these products
become more uniform, we would not recommend interchangeability of levothyroxine preparations.
(Henry Ford Hosp MedJ 1988;36:64-5)

I

n 1980 we demonsttated that the mean thyroxine content can be
different in generic tablets when compared to that of brand name
products. In addition, we demonstrated that a brand name product (Synthroid®) had only 78% of expected potency (1). Since
then, the United States Pharmacopeia (USP) requirements have
been modified so that manufacturers must evaluate levothyroxine content by high-performance liquid chromatography
(HPLC) (2). In 1984 we reported that Synthroid® had been reformulated and had 100% of expected potency (3). We reassessed
the content of a number of manufacturers' products using HPLC
to determine if these products are currently more uniform.

Materials and Methods
Ten different levothyroxine products manufactured by six
companies were analyzed by HPLC (Applied Analytical Laboratories, Wilmington, NC) (2). Local drugstores were contacted
until ten different levothyroxine products were obtained.
Between 17 and 21 tablets of each product were analyzed.
The tablets were split into two groups, and each group was
batch-analyzed separately. The analysis for each product was
completed in one day, and all products were analyzed over a
three-day period. Analysis of each extraction was duplicated.
Since two batch extractions were done on each product, each
group of tablets was assayed four times. The only exception was
product 10, which was submitted twice and treated as two separate products. Therefore, product 10 was analyzed eight times.
All tablets were 0.1 mg strength and were purchased in the fall of
1986. The assays were performed in June 1987.

Results
The results of our analyses are shown in the Table. Nine products fell within the USP requirement of ± 10%, but product 10
had only 47% of expected potency.
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Table
Thyroxine Content of 100 pg Tablets*
Expiration

Product
1
2
3
4
5
6
7
8
9
10

Manufacturer
A
B
C

c
cD
cll
F
C

% of Expected
Contentt
95
>)4
95
96
102
91
9S
96
100
47 f48t
145

Date
(month/year)
2/88
1/88
3/88
5/88
12/87
10/88
4/88
1/89
10/87
7/87

*These levothyroxine products were distributed under ten different labels.
tCoefficient of variation < 1.8%.
tTwo separate submissions: coefficient of variation - 3.6% for combined analysis.

Discussion
A recent study by Dong et al (4) showed frequent nonequivalence of levothyroxine products by tablet HPLC analysis.
However, these levothyroxine products were purchased in 1981,
before the introduction of the HPLC requirement for manufacturers. We suspect that the new USP HPLC requirement has improved the uniformity of levothyroxine products. However, Fish
et al (5) recently reported that one generic product had only 34%
of expected potency. Our data show that yet another company
had at least one lot (product 10) with less than expected potency
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(47%). We admit that our study is limited. To better estimate the
magnitude of the problem, a larger study evaluating different
lots, different time periods, and different tablet strengths is
needed. We hope this paper will stimulate investigators at research centers where such a study may be feasible.
The Food and Dmg Administration currently does not recommend interchangeability of levothyroxine products (6). Nevertheless, generic levothyroxine products are available and are
being interchanged for each other and for the brand name products, at least in Michigan. The FDA's advice is not binding on
the United States, and each state may allow interchangeability
for the products that the FDA considers not interchangeable (6).
We are concemed that levothyroxine products still show significant variability by HPUC (in vitro) testing. The USP has no requirement for bioavailability (in vivo) studies for levothyroxine
products (7). Until levothyroxine products become more uniform, we agree with the FDA's position that these products not
be interchanged. We hope that levothyroxine products will continue to be improved in the future.
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